Speakers

Andrew Anzalone, MD, PhD

Co-Founder and Head of Platform

Prime Medicine

David Craik, PhD

Professor of Biomolecular Structure

University of Queensland

Devan Shah

Founder & Chief Executive Officer

RNAV8 Bio

Fernando Albericio, PhD

Research Professor, School of Chemistry

University of Kwazulu-Natal

Florence Brunel, PhD

Senior Principal Scientist

Novo Nordisk

Fran Wincott, PhD

President

Wincott & Associates, LLC

Ian Huggins, PhD

Senior Director, Delivery Services

Aerska

John Zuris, PhD

Principal

John Zuris Consulting LLC

Kathryn Ackley, PhD

CMC Consultant Specializing in Oligonucleotides

Independent Consultant

Li Xiao, PhD

Director, Synthetic Molecule Design & Development

Eli Lilly and Company

Lori Troup

Director of Analytical Development

Novo Nordisk

Louise Dalboge, PhD

Chief Scientific Officer

Gubra Biotech

Marc Jacob, PhD

Head of Strategic Development, Chromatography Products

YMC America

Matteo Villain, PhD

Vice President of Peptides and Oligonucleotides

Veranova

Mike Webb, Ph.D.

Founder and CEO

Mike Webb Pharma

Patrick Knerr, PhD

Vice President, Metabolic Translational Research

Indiana Biosciences Research Institute

Patrick Reid, PhD

President and CEO

PeptiDream, Inc.

Ranganath Gopalakrishnan, PhD

Senior Director and Senior Principal Scientist

Zealand Pharma

Rubina Parmar,

PhD

Atlas Ventures

Saul Martinez Montero, PhD

Executive Director, RNA Therapeutics

Dyne Therapeutics

Seth Alexander, PhD

Director, Enterprise AI

Prime Medicine

Troels Koch, PhD

Chief Technology Officer

Cora Biosciences